News from genelux corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 11, 2020, 08:05 ET V2ACT Therapeutics™, LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer

V2ACT Therapeutics™, LLC today announced that the Company has obtained permission from the U.S. Food and Drug Administration (FDA) on an...


Sep 25, 2020, 19:00 ET Genelux Announces Closing of a Strategic Financing Transaction

Genelux Corporation, a privately-held clinical-stage immunotherapy company, today announced that it has entered into a convertible note and warrant...


Sep 16, 2020, 08:05 ET Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant/Refractory Ovarian Cancer at ESMO Virtual Congress 2020

Genelux Corporation, a privately-held biopharmaceutical company, today announced that data from the Phase 2 VIRO-15 study evaluating its lead...


Sep 10, 2020, 08:05 ET Genelux Announces Oral Plenary Presentation of VIRO-15 Phase 2 Trial Data at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society

Genelux Corporation, a privately-held biopharmaceutical company, today announced that the abstract covering data from the VIRO-15 Phase 2 trial...


Jun 04, 2020, 08:05 ET Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers

Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on...


May 07, 2020, 08:05 ET Genelux Corporation Announces Productive Type C Meeting with FDA

Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting with the U.S. Food and...


Jun 04, 2018, 07:07 ET Results from Genelux Corporation's Phase 1b Trial of GL-ONC1 in Recurrent Ovarian Cancer to be presented at the ASCO Annual Meeting 2018

Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today ...


Jan 04, 2018, 12:15 ET Genelux Announces Gynecologic Oncology Associates/Women's Cancer Research Foundation as New Site for the Ongoing Phase 2 VIRO-15 Study

Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, is...


Sep 27, 2017, 16:48 ET Genelux Initiates Phase 2 Clinical Trial of GL-ONC1 in Recurrent Ovarian Cancer

Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today ...


Nov 18, 2013, 10:08 ET Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013's 'Top Oncology Projects to Watch'

Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company's lead product candidate, GL-ONC1, has ...


Aug 04, 2011, 03:16 ET Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors

Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and...


Jan 24, 2011, 12:00 ET Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive

Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and...


Jan 12, 2011, 07:00 ET Genelux Corporation Appoints Jodi Devlin as President

Genelux Corporation, a privately held, San Diego-based biopharmaceutical company developing novel therapies against cancer, today announced that its...